+0.840 (+1.92%)
Range 43.280 - 45.800   (5.82%)
Open 43.510
Previous Close 43.800
Buy Price 44.460
Buy Volume 8
Sell Price 44.670
Sell Volume 8
Volume 1,671,452
Value -
Measurement Type Value
EPS (USD) 0.665
Trailing EPS (USD) -0.239
NAV (USD) 4.821
Cash In Hand (USD) 2.144
Dividend -
Dividend Yield (%) -
PE 65.912
Trailing PE -
Price / NAV 9.085
Price / Cash In Hand 20.428
Issued & Paid-up Shares 102,292,000
Treasury Shares -
Market Cap (M) 4,480.39
Par Value (USD) n.a.
Beta - 75 Days 0.916
R-Squared - 75 Days(%) 4.98
Beta - 500 Days 0.782
R-Squared - 500 Days(%) 8.06
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
Index Components
Delayed prices. Updated at 24 Sep 2020 04:00.
Data powered by

Upcoming Events

* Stock event date based on US timezone.


Release Date 15 Dec 2020
View All Events


Arrowhead Research Corporation (Arrowhead) is a biopharmaceutical company developing targeted RNAi therapeutics. The Company is leveraging its drug delivery technologies to develop drugs based on the RNA interference mechanism that silences disease-causing genes. Arrowhead technologies also enable partners to create peptide-drug conjugates that specifically home to cell types of interest while sparing off-target tissues. Arrowhead�s pipeline includes clinical programs in chronic hepatitis B virus and partner-based programs in obesity and oncology. ARC-520 is an RNAi-based therapeutic designed to treat chronic hepatitis B virus (HBV) infection. Arrowhead�s anti-obesity drug candidate, Adipotide, selectively destroys the blood supply that supports the growth of unhealthy fat by the targeted induction of apoptosis (cell death) in the vasculature of adipose tissue. In April 2012, the Company acquired Alvos Therapeutics, Inc.

Loading Chart...